Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment

Table 4

Complications of patients who received SD-CCRT and BioRT.

Characteristic	SD-CCRT (𝑛=116)	BioRT (𝑛=54)	𝑃 value
Neutropenia			0.003
Grade 1∼2	33 (28.5%)	10 (18.5%)
Grade 3∼4	20 (17.2%)	0 (0.0%)
Anemia			0.000
Grade 1∼2	88 (75.8%)	26 (48.1%)
Grade 3∼4	5 (4.3%)	0 (0.0%)
Thrombocytopenia			0.000
Grade 1∼2	114 (98.3%)	14 (26.0%)
Grade 3∼4	0 (0.0%)	0 (0.0%)
Mucositis			0.747
Grade 1∼2	47 (40.5%)	22 (40.7%)
Grade 3∼4	56 (48.3%)	25 (46.3%)
Radiation dermatitis			0.033
Grade 1∼2	79 (68.1%)	24 (44.4%)
Grade 3∼4	2 (1.7%)	2 (3.7%)
Skin acne			0.000
Grade 1∼2	0 (0.0%)	33 (61.1%)
Grade 3∼4	0 (0.0%)	4 (7.4%)
Nausea/vomiting			0.142
Grade 1∼2	6 (5.2%)	0 (0.0%)
Grade 3∼4	2 (1.7%)	0 (0.0%)
Diarrhea			0.494
Grade 1∼2	0 (0.0%)	0 (0.0%)
Grade 3∼4	1 (0.9%)	0 (0.0%)
Acute kidney injury			0.089
Grade 1∼2	6 (5.2%)	0 (0.0%)
Grade 3∼4	0 (0.0%)	0 (0.0%)